Corbus Pharmaceuticals Initiates "RESOLVE-1" Phase 3 Study in Systemic Sclerosis

Marketwired Thursday, 14 December 2017 ()
NORWOOD, MA--(Marketwired - December 14, 2017) -

· Systemic sclerosis is a rare, serious chronic autoimmune disease with no approved therapy
· Affects approximately 90,000 individuals in US and EU and associated with 10-year mortality of 40-60%
👓 View on full article
0
shares		Share on
FacebookShare on
TwitterPost on 
RedditShare by
Email